

NOW AVAILABLE

# pms-PROGESTERONE 200 mg



The **only** 200 mg progesterone capsule available



Sunflower-oil based formula



pms-PROGESTERONE (micronized progesterone) is indicated for women with an intact uterus as an adjunct to postmenopausal estrogen replacement therapy to significantly reduce the risk of endometrial hyperplasia and carcinoma.<sup>1</sup>

# New 200 mg capsule offers greater convenience for your patients

Patients now only need to take **half** the number of capsules—for the same total daily dose\*

When you receive a prescription for progesterone, consider *NEW* pms-PROGESTERONE 200 mg



Consult the product monograph at <https://health-products.canada.ca/dpd-bdpp/index-eng.jsp> for important information about:

- Contraindications in patients with liver dysfunction or disease; personal history of known or suspected estrogen-dependent or progestin-dependent malignant neoplasia; endometrial hyperplasia; undiagnosed abnormal genital bleeding; known or suspected pregnancy; active or past history of arterial thromboembolic disease; classical migraine; active or past history of confirmed venous thromboembolism or active thrombophlebitis; partial or complete loss of vision due to ophthalmic vascular disease.

- Most serious warnings and precautions regarding increased risk of myocardial infarction, stroke, invasive breast cancer, pulmonary embolism and deep vein thrombosis in postmenopausal women receiving treatment with combined conjugated equine estrogens (CEE) and medroxyprogesterone acetate; increased risk of stroke and deep vein thrombosis in hysterectomized women treated with CEE-alone; increased risk of probable dementia in postmenopausal women 65 years of age or older.
- Other relevant warnings and precautions regarding transient and occasional somnolence or dizziness, ovarian cancer, increased risk of coronary heart disease, increased blood pressure (monitor), worsening of glucose tolerance and lipid metabolism, women with familial

hyperlipidemias and porphyria, patients with metabolic and malignant bone diseases associated with hypercalcemia and in patients with renal insufficiency, vaginal bleeding, patients with a history of biliary disorders, monitor patients suspected of having hepatic disease, systemic lupus erythematosus, cerebrovascular insufficiency, dementia, exacerbation of epilepsy, fluid retention, asthma.

- Conditions of clinical use, adverse reactions, drug interactions and dosing instructions.

The product monograph is also available through our medical information department at 1-888-550-6060 or by email at [medinfo@pharmascience.com](mailto:medinfo@pharmascience.com).

\* For those patients prescribed a total daily dose of 200 mg.

**Reference: 1.** <sup>†</sup>pms-PROGESTERONE (progesterone capsules) 200 mg Product Monograph. Pharmascience Inc., August 20, 2018.

© 2019 Pharmascience Inc.

6111 Royalmount Avenue  
Montreal, Quebec  
H4P 2T4 Canada  
Phone: 1-800-340-9735

